Skip to main content

Actinogen Medical (AU:ACW) — Company Overview, News & Financial Data

Actinogen Medical logo
ACW Actinogen Medical
Actinogen Medical primary media
Company profile

Actinogen Medical

About

Explore Australia companies

Actinogen (ASX:ACW) is a clinical-stage biopharmaceutical company developing innovative treatments for cancer and other diseases. The company's lead product candidate, Xanamem, is a novel small molecule that targets the DNA damage response pathway. Xanamem is currently in Phase 2 clinical trials for the treatment of advanced pancreatic cancer and in Phase 1 clinical trials for the treatment of advanced solid tumours and acute myeloid leukaemia. Actinogen is also developing a second product candidate, ACT-701, which is a targeted therapy that is currently in preclinical development for the treatment of solid tumours.

Snapshot

Public AUOwnership
1999Year founded
17Employees
New South Wales, AustraliaHead office
Loading Map...
Global footprint

Operations

All Locations
Australia

Products and/or services of Actinogen Medical

  • Xanamem: A novel small molecule that targets the DNA damage response pathway, currently in Phase 2 clinical trials for the treatment of advanced pancreatic cancer and in Phase 1 clinical trials for the treatment of advanced solid tumours and acute myeloid leukaemia.
  • ACT-701: A targeted therapy that is currently in preclinical development for the treatment of solid tumours.
  • Cognitive impairment in early Alzheimer's Disease: A Phase 2b trial is ongoing to evaluate the efficacy and safety of Xanamem in patients with the early stages of Alzheimer's Disease.
  • Cognitive impairment in Major Depressive Disorder: A Phase 2a trial is currently enrolling patients to evaluate the efficacy and safety of Xanamem in patients with Cognitive Impairment and Depressive Disorder.
  • Anxiety, sleep & behavioural problems in Fragile X Syndrome: A Phase 2a trial is planned to evaluate the efficacy and safety of Xanamem in patients with Fragile X Syndrome.
  • Cortisol Hypothesis: Actinogen is developing therapies that target the cortisol hypothesis, which states that dysregulated brain cortisol plays a role in the development and progression of a variety of neurological diseases.

Actinogen Medical executive team

  • Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.MD, CEO & Director
  • Mr. William Edward Souter BCom, IPAA, LLB (Adel)Chief Financial Officer
  • Dr. Dana C. Hilt M.D.Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board
  • Mr. Andrew B. Udell B.Sc., M.B.A.Chief Commercial Officer
  • Mr. Michael RobertsHead of Investor Relations & Corporate Communications
  • Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.Head of Clinical Pharmacology & Lead Physician and Depression
  • Dr. Fujun Li Ph.D.Head of Manufacturing
  • Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary